SG Americas Securities LLC increased its holdings in NovoCure Limited (NASDAQ:NVCR – Free Report) by 346.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,245,541 shares of the medical equipment provider’s stock after purchasing an additional 966,735 shares during the period. SG Americas Securities LLC’s holdings in NovoCure were worth $13,576,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Morgan Stanley increased its holdings in shares of NovoCure by 453.4% during the 4th quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock valued at $65,554,000 after acquiring an additional 4,153,741 shares during the last quarter. Soleus Capital Management L.P. boosted its position in NovoCure by 25.0% during the second quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock worth $122,897,000 after purchasing an additional 1,382,888 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in NovoCure by 1,093.2% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,223,755 shares of the medical equipment provider’s stock worth $15,823,000 after purchasing an additional 1,121,192 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in NovoCure during the fourth quarter valued at approximately $11,991,000. Finally, Millennium Management LLC raised its position in shares of NovoCure by 106.5% in the third quarter. Millennium Management LLC now owns 1,335,490 shares of the medical equipment provider’s stock valued at $17,255,000 after purchasing an additional 688,710 shares during the period. 84.61% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, Director Allyson J. Ocean sold 2,945 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the sale, the director owned 11,324 shares in the company, valued at approximately $178,579.48. This trade represents a 20.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director W Anthony Vernon sold 2,945 shares of NovoCure stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the sale, the director directly owned 197,657 shares in the company, valued at approximately $3,117,050.89. This trade represents a 1.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 51,943 shares of company stock worth $893,171. 5.52% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on NovoCure
NovoCure Stock Up 2.5%
Shares of NVCR stock opened at $15.43 on Friday. NovoCure Limited has a 12 month low of $9.82 and a 12 month high of $18.92. The firm has a market cap of $1.79 billion, a PE ratio of -10.08 and a beta of 0.93. The stock has a 50 day moving average of $15.95 and a 200-day moving average of $13.65. The company has a quick ratio of 2.70, a current ratio of 2.90 and a debt-to-equity ratio of 0.71.
NovoCure (NASDAQ:NVCR – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). NovoCure had a negative net margin of 25.66% and a negative return on equity of 50.82%. The business had revenue of $174.06 million during the quarter, compared to the consensus estimate of $167.77 million. During the same period in the prior year, the company posted ($0.31) earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. On average, equities analysts predict that NovoCure Limited will post -1.55 EPS for the current year.
NovoCure Company Profile
NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.
Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.
Featured Stories
- Five stocks we like better than NovoCure
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Want to see what other hedge funds are holding NVCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NovoCure Limited (NASDAQ:NVCR – Free Report).
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.
